Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Update on the SENTRY trial: selinexor plus ruxolitinib in JAK-naive myelofibrosis

Prithviraj Bose • 18 Sep 2026
SOHO 2026
Myelofibrosis Ruxolitinib Selinexor
SENTRY

Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on the Phase III SENTRY trial (NCT04562389), which evaluated selinexor plus ruxolitinib versus placebo plus ruxolitinib in patients with JAK inhibitor-naive myelofibrosis, highlighting an unexpected statistically significant survival benefit. Dr Bose notes that the trial is being kept blinded to further understand this survival benefit and that spleen reduction correlated with better survival in both arms. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Prithviraj Bose

Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
2:21
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
Prithviraj Bose • 18 Sep 2026
Phase II SUMMIT: bezuclastinib reduces symptoms and disease burden in systemic mastocytosis
4:30
Phase II SUMMIT: bezuclastinib reduces symptoms and disease burden in systemic mastocytosis
Prithviraj Bose • 18 Sep 2026
Looking beyond JAK inhibitor efficacy in myelofibrosis: side effects, safety, and dosing
3:21
Looking beyond JAK inhibitor efficacy in myelofibrosis: side effects, safety, and dosing
Prithviraj Bose • 18 Sep 2026

Related Videos

Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
2:21
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
Prithviraj Bose • 18 Sep 2026
Looking beyond JAK inhibitor efficacy in myelofibrosis: side effects, safety, and dosing
3:21
Looking beyond JAK inhibitor efficacy in myelofibrosis: side effects, safety, and dosing
Prithviraj Bose • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals